On Thursday, CTI BioPharma Corp (NASDAQ:CTIC)’s shares showed no change to $2.09.
CTI BioPharma Corp (CTIC) and Baxter International’s BioScience business (BAX) recently declared new patient-stated outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 – from the Phase 3 PERSIST-1 study. As recently stated at the American Society of Clinical Oncology (ASCO) annual meeting, results show a noteworthy reduction in the Total Symptom Score (TSS) (the proportion of patients with a 50 percent or greater reduction in TSS from baseline to Week 24), and in each individual common disease-related symptom, from baseline to Week 24, in patients treated with pacritinib contrast to best accessible therapy (exclusive of a JAK inhibitor) (BAT). These PROs, in addition to other quality of life measures, will be presented at the 20th Congress of European Hematology Association (EHA) by Adam Mead, M.D., Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom in an oral presentation on Sunday, June 14, 2015 at 12:15 CEST (abstract #LB2072). These data were also selected for inclusion in the official EHA Press Briefing which occurred recently (Friday, June 12, 2015) at 08:30 CEST. As formerly stated, the PERSIST-1 trial met its primary endpoint of spleen volume reduction of 35 percent or greater from baseline to Week 24 as measured by MRI/CT scan.
Myelofibrosis is a rare blood cancer associated with significantly reduced quality of life and shortened survival. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia, and red blood cell transfusion requirements enhances significantly. Among other complications, most patients with myelofibrosis present with enlarged spleens (splenomegaly), in addition to many other potentially devastating physical symptoms such as abdominal discomfort, bone pain, feeling full after eating little, severe itching, night sweats, and extreme fatigue.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. T
BB&T Corporation (NYSE:BBT)’s shares dropped -0.63% to $40.90.
BB&T Corporation (BBT) declared it has received regulatory approval from the Federal Reserve, the FDIC and all required state regulators to acquire The Bank of Kentucky. The transaction closing and systems conversion is predictable on June 19, 2015.
Headquartered in Crestview Hills, Ky., The Bank of Kentucky has 32 banking offices in Northern Kentucky and Cincinnati. The merger comprises $1.6 billion in deposits, $1.3 billion in loans, and total assets of $1.9 billion based on March 31, 2015, balances. The planned acquisition was originally declared Sept. 8, 2014.
BB&T Corporation operates as a financial holding company that provides various banking and trust services for retail and commercial clients. It operates in six segments: Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Services, and Financial Services. The company’s deposit products comprise noninterest-bearing checking accounts, interest-bearing checking accounts, savings accounts, money market deposit accounts, certificates of deposit, and individual retirement accounts. Its loan portfolio comprises commercial, financial and agricultural, real estate construction and land development, real estate mortgage, and consumer loans.
At the end of Thursday’s trade, Banro Corporation (USA) (NYSEMKT:BAA)‘s shares surged 5.92% to $0.358.
Banro Corporation (USA) (BAA) provides an update of its Mineral Resource and Mineral Reserve estimates at its wholly-owned projects on the Twangiza-Namoya gold belt in the Democratic Republic of the Congo (“DRC”). The annual review of Mineral Resources and Mineral Reserves at the Company’s four core projects, Twangiza, Namoya, Lugushwa and Kamituga, has resulted in a substantial enhance in Mineral Reserves with the conversion of transition and fresh Mineral Resources into Mineral Reserves at Twangiza.
Highlights
- The Twangiza Proven and Probable Reserves raised 59% to 1.64 million ounces (“Moz”) of gold (22.38Mt @ 2.28g/t Au) with the inclusion of non-oxide materials in the reserve pit shell which have been proven economically treatable with the existing plant. This expands the Twangiza mine life utilizing the existing plant to 14 years.
- At Namoya, the Proven and Probable Mineral Reserves have reduced 5% to 1.27 Moz (20.53Mt @ 1.92g/t Au), primarily due to mining depletion.
- Banro’s overall Mineral Reserves have grown by 23% to 2.91 Moz (42.91Mt @ 2.11g/t Au) at US$1,200/oz gold price.
During 2014, the Company scaled down its exploration activities at its Twangiza, Namoya, Lugushwa and Kamituga projects and focused its geological expertise on supporting the production growth at Twangiza, development at the Namoya Mine and identification of near mine high grade targets.
In order to consolidate Banro’s position on the various exploration sites, some limited exploration activities are planned for 2015 using small teams focused on generating new oxide targets in Lugushwa and Kamituga. At Namoya, exploration drilling activities will be focused on near mine resource upgrade and resource generation activities. The primary objective is to upgrade inferred resources within the Namoya Summit-Filon B reserve pit into a higher confidence resource for conversion into mineral reserves. Another objective is to define additional near mine oxide resources within 5 kilometers of the Run-Of-Mine pad. At Twangiza, delineation drilling will be focused on near mine oxide resources generation on the Twangiza East and West mineralization.
Banro Corporation, together with its auxiliaries, engages in the exploration, development, and production of mineral properties. It primarily explores for gold. The company holds a 100% interest in 4 gold properties, counting Twangiza, Namoya, Lugushwa, and Kamituga comprising 13 exploitation permits that cover an area of about 2,612 square kilometers in the South Kivu and Maniema provinces of the Democratic Republic of the Congo.
Ocwen Financial Corp (NYSE:OCN), ended its Thursday’s trading session with 0.76% gain, and closed at $10.65.
NAACP Florida State Conference declared the second in a series of local homeowner outreach events held in partnership with Ocwen Financial Corporation (OCN), a leading financial services holding company. The Assist & Hope for Homeowners event, planned for Saturday, June 20, will provide Florida homeowners with opportunities to learn about loan modification programs, counting principal reduction, which can assist make their homes more affordable.
Following a very successful series debut in Chicago, the event will bring Ocwen customers together with United States Department of Housing and Urban Development (HUD) approved financial counselors and Ocwen Home Retention Agents, who can explore with homeowners potential loan modification options.
In Florida specifically, the situation is dire. According to data collected by RealtyTrac, just this past April, one out of every 425 Florida housing units was in foreclosure. In 2014, the state had the highest foreclosure rate in the country.
Ocwen Financial Corporation, a financial services holding company, engages in servicing and origination of mortgage loans in the United States. Its Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset management services to owners of mortgage loans and foreclosed real estate. This segments’ residential servicing portfolio includes conventional, government insured, and non-agency loans.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
